Poorva Hemant Joshi

Dr. Poorva Hemant Joshi

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
AYAhmed Adel Ali Youssef
Ahmed Adel Ali Youssef
RTRuchi Thakkar
Ruchi Thakkar
SSSAMIR SENAPATI
SAMIR SENAPATI
PJPoorva Hemant Joshi
Poorva Hemant Joshi
NDNarendar Dudhipala
Narendar Dudhipala
SMSoumyajit Majumdar
Soumyajit Majumdar
Ocular bacterial infections can lead to serious visual disability without proper treatment. Moxifloxacin (MOX) has been approved by the US Food and Drug Administration as a monotherapy for ocular bacterial infections and is available commercially as an ophthalmic solution (0.5% w/v). However, precorneal retention, drainage, and low bioavailability remain the foremost challenges associated with current commercial eyedrops. With this study, we aimed to design a MOX-loaded nanoemulsion (NE; MOX-NE) with mucoadhesive agents (MOX-NEM) to sustain MOX release, as well as to overcome the potential drawbacks of the current commercial ophthalmic formulation. MOX-NE and MOX-NEM formulations were prepared by hot homogenization coupled with probe sonication technique and subsequently characterized. The lead formulations were further evaluated for in vitro release, ex vivo transcorneal permeation, sterilization, and antimicrobial efficacy studies. Commercial MOX ophthalmic solution was used as a control. The lead formulations showed the desired physicochemical properties and viscosity. All lead formulations showed sustained release profiles a period of more than 12 h. Filtered and autoclaved lead formulations were stable for one month (the last time point tested) under refrigeration and at room temperature. Ex vivo transcorneal permeation studies revealed a 2.1-fold improvement in MOX permeation of the lead MOX-NE formulation compared with Vigamox® eyedrops. However, MOX-NEM formulations showed similar flux and permeability coefficients to those of Vigamox® eyedrops. The lead formulations showed similar in vitro antibacterial activity as the commercial eyedrops and crude drug solution. Therefore, MOX-NE and MOX-NEM formulations could serve as effective delivery vehicles for MOX and could improve treatment outcomes in different ocular bacterial infections.

15 August 2023 in Antibiotics
Verified
Journal Article
Open access
PDF file
PJPoorva Hemant Joshi
Poorva Hemant Joshi
AYAhmed Adel Ali Youssef
Ahmed Adel Ali Youssef
MGMihir Ghonge
Mihir Ghonge
CVCorinne Varner
Corinne Varner
STSiddharth Tripathi
Siddharth Tripathi
SMSoumyajit Majumdar
Soumyajit Majumdar
Bacterial conjunctivitis (BC) entails inflammation of the ocular mucous membrane. Early effective treatment of BC can prevent the spread of the infection to the intraocular tissues, which could lead to bacterial endophthalmitis or serious visual disability. In 2003, gatifloxacin (GTX) eyedrops were introduced as a new broad-spectrum fluoroquinolone to treat BC. Subsequently, GTX use was extended to other ocular bacterial infections. However, due to precorneal loss and poor ocular bioavailability, frequent administration of the commercial eyedrops is necessary, leading to poor patient compliance. Thus, the goal of the current investigation was to formulate GTX in a lipid-based drug delivery system to overcome the challenges with the existing marketed eyedrops and, thus, improve the management of bacterial conjunctivitis. GTX-NLCs and SLNs were formulated with a hot homogenization–probe sonication method. The lead GTX-NLC formulation was characterized and assessed for in vitro drug release, antimicrobial efficacy (against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa), and ex vivo permeation. The lead formulation exhibited desired physicochemical characteristics, an extended release of GTX over a 12 h period, and was stable over three months at the three storage conditions (refrigerated, room temperature, and accelerated). The transcorneal flux and permeability of GTX from the GTX-NLC formulation were 5.5- and 6.0-fold higher in comparison to the commercial eyedrops and exhibited a similar in vitro antibacterial activity. Therefore, GTX-NLCs could serve as an alternative drug delivery platform to improve treatment outcomes in BC.

10 April 2024 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
AYAhmed Adel Ali Youssef
Ahmed Adel Ali Youssef
MAMuna Hayder Abdelrahman
Muna Hayder Abdelrahman
MGMona M. Geweda
Mona M. Geweda
CVCorinne Varner
Corinne Varner
PJPoorva Hemant Joshi
Poorva Hemant Joshi
SMSoumyajit Majumdar
Soumyajit Majumdar